A new partnership between ProImmune, Ltd. And the University of Texas Medical Branch (UTMB) aims to accelerate the study of the world’s most dangerous viruses. By integrating advanced molecular binding tools with high-containment laboratory expertise, the collaboration seeks to improve how scientists detect and analyze viral proteins in real-time, potentially shortening the window between the emergence of a pathogen and the development of a medical countermeasure.
The initiative centers on the use of Ankyrons—a specialized class of binding reagents—within the Galveston National Laboratory (GNL). This facility is one of the few in the United States equipped to handle “high-consequence” pathogens, which are diseases that pose a severe threat to public health and require the highest levels of biological security to study safely.
Under the terms of the agreement, researchers will evaluate how these molecular tools perform in complex experimental systems. The primary goal is to achieve precise localization and functional interrogation of viral proteins, allowing scientists to see exactly where a virus is attacking a cell and how We see disrupting the host’s immune response.
Bridging the Gap in BSL-4 Research
Much of the work will take place in the laboratory of Dr. Courtney Woolsey, where the focus is on the immunopathology of emerging and endemic viruses. Because these pathogens are so lethal, they must be studied under Biosafety Level 4 (BSL-4) conditions—the maximum level of containment. In such an environment, every tool used must be highly efficient and compatible with stringent safety protocols.
The collaboration specifically targets viral protein function and immune dysregulation. By understanding the tissue-specific responses these viruses trigger, the team hopes to provide the foundational data necessary to inform the next generation of vaccines, and therapeutics. The ability to map these interactions with high precision is critical for developing drugs that can block viral entry or replication without harming the patient’s own cells.
The initial phase of the research will focus on a specific set of high-priority pathogens. The teams are validating Ankyrons against several viral targets of major global concern:
- Ebolaviruses: Including the Zaire, Sudan, and Reston strains.
- Bundibugyo virus: A hemorrhagic fever virus related to Ebola.
- Mpox virus: The agent responsible for the recent global outbreaks of monkeypox.
- Human Enterovirus 71: A pathogen known to cause severe neurological complications.
The Science of Ankyrons: A Faster Alternative to Antibodies
To understand why this collaboration is significant, one must look at the limitations of traditional research tools. For decades, scientists have relied on antibodies to “tag” and track proteins. However, producing high-quality antibodies often requires animal immunization, a process that can be slow, inconsistent, and ethically complex.
Ankyrons represent a departure from this traditional method. They are small, single-domain binding reagents (approximately 15 kDa) based on an engineered ankyrin-repeat scaffold. Unlike antibodies, Ankyrons are generated through a fully in vitro, high-throughput selection process. In other words they are created in a laboratory setting without the need for animals.
This synthetic approach offers several advantages for pandemic preparedness:
- Speed: They can be rapidly identified and optimized, which is essential when a new “Disease X” emerges and researchers have only days or weeks to find a way to detect it.
- Specificity: The engineered scaffold allows for high affinity and precision, reducing the “noise” or false positives often found in complex biological samples.
- Scalability: ProImmune reports that Ankyrons are already available for 60 different pathogens and disease vectors, and the platform can be pivoted quickly to target new threats.
Nikolai Schwabe, CEO of ProImmune, Ltd., emphasized the synergy between the technology and the environment. “Ankyrons and our powerful automated high throughput parallel discovery platform are particularly well suited for demanding research environments such as emerging infectious diseases, enabling detection and interrogation of viral proteins and study of multiple rapidly emerging infectious diseases simultaneously,” Schwabe said. He added that working with the Woolsey laboratory at GNL allows the company to validate these reagents in biologically relevant systems to strengthen pandemic preparedness.
Implications for Global Health Security
The ability to simultaneously study multiple emerging diseases is a strategic shift in how public health agencies approach biosurveillance. Traditionally, research has been reactive—waiting for an outbreak to occur before developing the tools to study it. By building a library of validated reagents for high-consequence pathogens, the scientific community moves toward a proactive stance.
| Feature | Traditional Antibodies | Ankyron Reagents |
|---|---|---|
| Production Method | Animal Immunization | In vitro High-Throughput |
| Development Speed | Slow/Moderate | Rapid |
| Size | Large (~150 kDa) | Small (~15 kDa) |
| Consistency | Variable by batch/animal | Highly reproducible |
For the broader medical community, this means that if a new strain of a virus appears, the “blueprint” for detection may already exist. The precision of these tools also means that the transition from laboratory discovery to clinical application—such as a diagnostic test or a targeted therapy—could be significantly accelerated.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. For guidance on infectious diseases or vaccinations, please consult a licensed healthcare provider or official public health agencies such as the CDC or WHO.
The next phase of the collaboration will involve the continued validation of these reagents within the GNL’s BSL-4 environment, with the goal of refining the tools for broader use in infectious disease research. Official updates on the findings from the Woolsey laboratory are expected as the validation studies progress.
We invite readers to share their thoughts on the role of synthetic reagents in pandemic preparedness in the comments below.
